Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Shuang Qin(Guangzhou Women and Children Medical Center), Suxia Luo(Zhengzhou University)Molecular CancerNovember 6, 201910.1186/s12943-019-1091-2Cited by 1,166SaveCiteExport RISWatch citationsRelated PapersPembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial|The Lancet Oncology|2023|614